Montanova Capital LLC Decreases Holdings in Fulcrum Therapeutics, Inc. $FULC

Montanova Capital LLC trimmed its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 43.9% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 3,680,921 shares of the company’s stock after selling 2,880,190 shares during the quarter. Montanova Capital LLC’s holdings in Fulcrum Therapeutics were worth $13,472,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. bought a new position in Fulcrum Therapeutics in the second quarter valued at about $32,297,000. Nantahala Capital Management LLC purchased a new position in Fulcrum Therapeutics in the second quarter worth about $20,038,646. Braidwell LP grew its stake in shares of Fulcrum Therapeutics by 1,294.7% during the 4th quarter. Braidwell LP now owns 3,061,222 shares of the company’s stock valued at $34,622,000 after purchasing an additional 2,841,734 shares during the period. Siren L.L.C. bought a new stake in shares of Fulcrum Therapeutics during the 4th quarter valued at about $22,054,000. Finally, First Turn Management LLC purchased a new stake in shares of Fulcrum Therapeutics during the 4th quarter valued at about $21,406,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Stock Up 1.0%

FULC stock opened at $3.89 on Tuesday. Fulcrum Therapeutics, Inc. has a twelve month low of $2.83 and a twelve month high of $15.74. The stock has a market cap of $296.81 million, a P/E ratio of -3.21 and a beta of 3.05. The business’s 50-day moving average price is $3.73 and its 200-day moving average price is $5.93.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). On average, equities research analysts expect that Fulcrum Therapeutics, Inc. will post -0.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Fulcrum Therapeutics news, Director Alan Ezekowitz sold 18,000 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $3.65, for a total value of $65,700.00. Following the completion of the transaction, the director directly owned 10,927 shares in the company, valued at $39,883.55. This represents a 62.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective on the stock. in a research note on Tuesday, June 2nd. JPMorgan Chase & Co. cut shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a report on Wednesday, June 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Friday, July 17th. Cantor Fitzgerald cut shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Finally, HC Wainwright downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, Fulcrum Therapeutics currently has a consensus rating of “Reduce” and a consensus price target of $8.20.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.